Urinary incontinence

Urinary incontinence, as defined by The International Continence Society, is the complaint of any involuntary leakage of urine.\(^1\) Urinary incontinence is a common problem throughout the world. In the UK alone, it has been estimated that there are more than 3.5 million sufferers.\(^2,3\)

Dr Natalia Price  MRCOG, Subspecialty trainee in Urogynaecology, John Radcliffe Hospital, Oxford
Mr Simon Robert Jackson FRCOG, Consultant Urogynaecologist John Radcliffe Hospital, Oxford
email natalia.price@doctors.org.uk

Urinary incontinence is a common symptom that can affect women of all ages, with a wide range of severity and nature. While rarely life-threatening, incontinence may seriously influence the physical, psychological and social wellbeing of affected individuals. The impact on the families and carers of women with UI may be profound, and the resource implications for the health service considerable.

Common causes of urinary incontinence in women

Stress urinary incontinence
The complaint of involuntary leakage of urine on effort or exertion, or on sneezing or coughing.

Urge urinary incontinence
The involuntary leakage of urine accompanied by, or immediately preceded by, a strong desire to pass urine (void). Urgency, with or without urge urinary incontinence, usually with frequency and nocturia is also defined as Overactive bladder syndrome (OAB).

Mixed urinary incontinence
The involuntary leakage of urine associated both with urgency and also with exertion, effort, sneezing or coughing. Usually, one of these is predominant; ie. either the symptoms of urge incontinence, or those of stress incontinence, are most bothersome.

Overflow incontinence
This occurs when the bladder becomes large and flaccid and has little or no detrusor tone or function. It is usually due to injury or insult, eg. postsurgery or postpartum. The bladder simply leaks when it becomes full.

Incontinence due to a fistula
Incontinence resulting from a vesicovaginal, ureterovaginal or urethrovaginal fistula.

Congenital incontinence
Congenital causes, eg. ectopic ureter.

Differential diagnosis/secondary causes
In both primary and secondary care, other conditions have to be excluded before the diagnosis can be made:
- Recurrent urinary tract infections (UTIs)
- Bladder outflow obstruction. This is uncommon in women unless there is a history of pelvic or incontinence surgery
- Severe chronic constipation can cause a physical outflow obstruction
- Psychological and metabolic causes of polydipsia and polyuria such as diabetes mellitus, diabetes insipidus or excessive fluid consumption
- Neurological abnormalities (spinal cord injuries, spina bifida, multiple sclerosis or upper motor neurone disease)
- Drugs, medications (eg. diuretics, ACE inhibitors, etc).

Approach to diagnosis

History
History taking in patients with of urinary incontinence guides the investigation and management by
evaluating symptoms, their progression and the impact of symptoms on lifestyle. A good clinical history will include enquiries about impact of the disease on quality of life by asking how the symptoms affect aspects of daily life and social, personal and sexual relationships. The onset of urinary symptoms, their duration and their severity should be recorded. The predominant bother symptom, eg. urgency, urge incontinence or stress incontinence, should be identified.

In addition to the above symptoms, the clinician should enquire about colorectal symptoms and genitourinary prolapse. Accompanying symptoms that may indicate the possibility of a more serious diagnosis and which require referral, such as haematuria, persisting bladder or urethral pain, or recurrent UTI, can also be identified when taking a urinary history.

**Clinical examination**

Clinical examination should include an abdominal examination to exclude abdominal mass or palpable bladder, a bimanual examination to exclude pelvic mass, and a vaginal examination. Neurological assessment of the lower limbs and perineum is required if a neurological cause is suspected.

Vaginal examination should include an assessment of urethral and bladder neck descent on straining, anterior vaginal wall mobility and concurrent uterovaginal prolapse. An assessment of pelvic floor strength should be made for all women with urinary stress incontinence. Pelvic floor strength is graded 0 to 5 on a modified Oxford scale, and endurance (i.e. length of time of maximum contraction) and the number of repeated contractions is also recorded.

**Key diagnostic tests**

This includes urinalysis, which is reagent strip testing of urine for leukocyte esterase, nitrates, protein, blood and glucose is a sensitive and cheap screening test. A urine microscopy and culture is reserved for those with a positive screening test result. Exclusion of infection is mandatory, as symptoms of do overlap with those of UTI.

A post-void residual check should be carried out (either by ultrasound scan or by catheterisation) if there are symptoms suggestive of incomplete bladder emptying. Diagnosis can be assisted with the use of a frequency/volume chart (urinary diary). This is a simple and practical method of obtaining objective quantification of fluid intake, functional bladder capacity and voiding behaviour. Frequency and times of voiding, voided volumes and leakage episodes (day and night) are all recorded for at least 24 hours and typically 3 days.

Finally, there are urodynamic investigations. These include uroflowmetry, post-void residual measurement, and urodynamic pressure-flow studies. These tests can help in identifying the cause of symptoms and planning treatment.

**Box 1: Clinical indications for urodynamic assessment**

- Complex mixed urinary symptoms (urge incontinence and stress incontinence)
- Symptoms suggestive of detrusor overactivity unresponsive to pharmacotherapy
- Voiding dysfunction with incomplete bladder emptying
- Neuropathic bladder disorder (videourodynamic preferred).

**Box 2: Women with urinary incontinence who have any of the following should receive urgent referral**

- Microscopic haematuria in women aged 50 years and older
- Visible haematuria
- Recurrent or persisting UTI associated with haematuria in women over 40
- Suspected malignant mass arising from pelvis or abdomen.
- Symptomatic prolapse that is visible at or below the vaginal introitus.
- The finding of a palpable bladder on bimanual or abdominal examination after voiding.

The NICE Referral Guidelines for Suspected Cancer (www.nice.org.uk/CG027) define urgent referral as the patient being seen within the national target for urgent referrals (currently 2 weeks).
and cystometry. It is important that any clinician referring a patient for such tests has an understanding of what the tests entail and the indications for it.

Management options

NICE in 2006 published guidelines on the management of urinary incontinence in women, which is a comprehensive document summarising the evidence-based management options. Based on this guidance, the current practice is that patients with urinary incontinence are categorised according to their symptoms into those with stress, mixed or urge urinary incontinence. Overall, approximately one half of all incontinent women complain of pure stress incontinence and 30–40% have mixed symptoms of stress and urge incontinence. Women with mixed urinary incontinence, who have an involuntary leakage associated with urgency and also with exertion, are treated according to the symptom they report to be the most troublesome. First treatment should commence on this basis. In mixed urinary incontinence, the treatment should be directed towards the predominant symptom.

Urge urinary incontinence (Overactive bladder syndrome)

Conservative treatment should be initiated in primary care. It is wise to start with the simplest of conservative therapies and progress through to treatments that are more radical, if necessary. Ideally, we should help the patient to become symptom-free, although this may not always be possible. The aim should be to give the patient more control and improve their quality of life. Realistic goals need to be discussed and agreed with the patient during the consultation. These might include:

- Being able to undertake their normal daily routine (eg. shopping, meetings, travel)
- Reducing the number of incontinence episodes
- Regaining the confidence to socialise, eg. go out to dinner with a partner.

Lifestyle changes and behavioural therapy

Reducing fluid intake, if the urinary diary suggests this is excessive, and cutting caffeinated products out of the diet will often have a dramatic effect. Simple advice such as this may be all that is required to cure frequency and urgency. Various drugs, such as diuretics and antipsychotics, alter bladder function and should be reviewed.

Bladder training lasting for a minimum of six weeks should be offered as first-line treatment to patients with OAB and with or without urinary incontinence. This can be in combination with anticholinergic therapy. The three main components of bladder training are patient education, timed voiding with systematic delay in voiding, and positive reinforcement. The patients should be asked to resist the sensation of urgency and void according to a timetable. A self-completed urinary diary should be used to monitor the times of voids. Conti

<table>
<thead>
<tr>
<th>Route of delivery</th>
<th>Adult dosage</th>
<th>Cost per 28 days**</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oxybutynin</strong></td>
<td>(a) 2.5–5mg, 1 to 4 times/day</td>
<td>£8.89 - £30.51</td>
</tr>
<tr>
<td></td>
<td>(b) 5–10 mg once daily (SR)</td>
<td>£12.34 - £24.68</td>
</tr>
<tr>
<td></td>
<td>One patch, twice/week (3·9mg/24hours)</td>
<td>£27.20</td>
</tr>
<tr>
<td>Transdermal patch</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Propiverine</strong></td>
<td>15mg, 2–4 times/day</td>
<td>£24.45 - £48.90</td>
</tr>
<tr>
<td><strong>Solifenacin</strong></td>
<td>5–10mg daily</td>
<td>£25.78 - £33.91</td>
</tr>
<tr>
<td><strong>Tolterodine</strong></td>
<td>(a) 1 – 2mg, twice daily</td>
<td>£30.56</td>
</tr>
<tr>
<td></td>
<td>(b) 4mg, once daily (SR)</td>
<td>£29.03</td>
</tr>
<tr>
<td><strong>Trospium</strong></td>
<td>20mg, twice daily</td>
<td>£24.27</td>
</tr>
<tr>
<td><strong>Darifenacin</strong></td>
<td>7·5 or 15 mg once daily (SR)</td>
<td>£26.13</td>
</tr>
<tr>
<td><strong>Fesoterodine</strong></td>
<td>4–8 mg once daily (SR)</td>
<td>£25.78</td>
</tr>
</tbody>
</table>

*SR – sustained release, ** Approximate costs to the NHS, 2008
the corresponding cure rates could be considerably lower than this.

Pharmacotherapy

Anticholinergics
Pharmacological suppression of detrusor overactivity with anticholinergics (antimuscarinics) is the most widely used treatment for this condition. Anticholinergic drugs block the muscarinic receptors that mediate detrusor smooth-muscle contraction and have a direct, relaxing effect on the detrusor muscle. There are a number of drug treatments available (see Box 3). They differ in their selectivity for various muscarinic receptors and some drugs have additional actions, such as direct smooth muscle effects. These drugs are essentially safe and, therefore, it would seem reasonable clinical practice to commence a short course of empirical treatment in cases where detrusor overactivity is suspected. If symptoms are not improved after one or two months of anticholinergics, the patient should be referred to a specialist clinic.

Immediate release non-proprietary oxybutynin should be offered to women with OAB or mixed urinary incontinence as first-line antimuscarinic drug treatment, if bladder training has been ineffective. If immediate release oxybutynin is not well tolerated, darifenacin, solifenacin, tolterodine, trosipum or an extended release or transdermal formulation of oxybutynin should be considered as alternatives:
- Oxybutynin, propiverine, tolterodine and trosipum chloride have been used for many years to treat OAB symptoms. Sustained release oxybutynin transdermal patches, which release 3.9 mg every 24 hours, have recently been launched in the UK.4,5
- Solifenacin and darifenacin are newer bladder-selective anticholinergic preparations. They are more recent useful additions to the list of available drugs and may possibly have a lower incidence of adverse effects.6,7,8
- Fesoterodine is the latest addition to the available list of drugs. It is a nonselective oral antimuscarinic agent that exerts its pharmacologic effects as a competitive muscarinic receptor antagonist.9,10
- Patients should be advised on the possibility of side effects before starting treatment. The dosage may need to be titrated against clinical efficacy and adverse effects profile. Some may tolerate particular preparation better than others and clinicians may need to try a number of preparations before finding one that suits the individual.11,12,13 Adverse effects of anticholinergics may include: dry mouth (in up to 30% of cases), constipation, blurred vision, nausea, dyspepsia and flatulence, palpitation and arrhythmia, dizziness, insomnia and skin reactions.

An early treatment review should be undertaken following any change in antimuscarinic drug therapy. If the treatment is effective in our practice we recommend continuation of pharmacotherapy with anticholinergics for six to nine months.

The role of oestrogens
Many women develop bladder-filling symptoms after the menopause. Oestrogen treatment in post-menopausal women improves symptoms of vaginal atrophy, such as vaginal dryness and irritation. In a review of ten randomised placebo-controlled trials, vaginal oestrogen administration was found to be superior to a placebo when considering symptoms of urgency, urge incontinence, frequency and nocturia.14

Complementary therapy
Patients who do not find conventional treatments acceptable often explore the use of complementary therapies for urinary incontinence and as adjuncts to conventional treatments. There is some evidence, albeit of poor quality, which shows that acupuncture may reduce nocturia and both stress and urge incontinence in the short term (up to four weeks) but it is unclear whether any particular area of acupuncture treatment is more effective than another. There is also limited evidence that hypnotherapy for patients with urinary incontinence secondary to detrusor overactivity may

Box 4: Contra-indications of anticholinergics

- Acute (narrow angle) glaucoma
- Myasthenia gravis
- Urinary retention or outflow obstruction
- Severe ulcerative colitis
- Gastro-intestinal obstruction
offer some benefit over the short term (up to six months). However, there is no evidence that herbal medicines work for urinary incontinence or OAB, apart from the usual placebo effect. No complementary therapies are presently recommended by NICE for the treatment of urinary incontinence or OAB.

New developments
Some new treatments, such as neuromodulation, sacral nerve stimulation and intravesical botulinum toxin injections, are showing considerable promise.

Botulinum toxin A (BTX) has the potential to revolutionise the management of OAB and refractory DO. It blocks neuromuscular transmission, causing the affected muscle to become weak. There is preliminary evidence of BTX injections showing remarkable efficacy in inhibiting the symptoms of OAB. The toxin is injected cystoscopically under local or general anaesthesia into the detrusor muscle in 10 to 30 different locations, while sparing the trigonum. Intravesical BTX does appear to reduce incontinence when compared with placebo, with results reported cure or improvement rates of 60–93% at three weeks to 12 months follow-up. Duration of response to a single dose is on average 6 months (range 3 to 12 months). The most common complication reported is voiding dysfunction and urinary retention (5–20%), which usually resolved as effect of the treatment wears off.

Neuromodulation and sacral nerve stimulation provides continuous stimulation of the S3 nerve root via an implanted electrical pulse generator and is thought to improve the ability to suppress detrusor contractions. It is being used increasingly in the treatment of refractory detrusor overactivity. Overall, neuromodulation has a 30–70% clinical success rate. Women should be offered sacral nerve stimulation on the basis of their response to preliminary percutaneous nerve evaluation. It is, however, a very expensive treatment, as the implant alone costs approximately £10,000. Insertion of the implant is an invasive procedure and life-long follow-up is required.

Surgical management
Surgery is reserved for those with debilitating symptoms and who have failed to derive benefit from medical and behavioural therapy. Procedures, such as bladder distention, detrusor myomectomy and augmentation cystoplasty, have limited efficacy and high rates of complications. Permanent urinary diversion is occasionally indicated in women with intractable incontinence.

Stress urinary incontinence (SUI)

Conservative management
Conservative treatment is again usually initiated in primary care. This involves treating the conditions predisposing to stress incontinence, for example through adjustment of lifestyle (weight reduction if BMI>30, smoking cessation, treatment of chronic cough and constipation.), pelvic floor exercises and pharmacotherapy.

Pelvic floor muscle training
Pelvic floor muscle training (PFMT) is an appropriate first line treatment for most women. The aim of pelvic floor exercise is to promote the woman’s awareness of her pelvic floor muscles and to improve their contractility and coordination. PFMT is more effective than no treatment. A trial of supervised PFMT of at least three months’ duration should be offered as first-line treatment to women with stress or mixed urinary incontinence. A PFMT programme should comprise at least eight contractions performed three times per day. If pelvic floor muscle training is beneficial, the exercise programme should be maintained. Exercise needs to be continued on a long-term basis to prevent recurrence of symptoms.

Biofeedback is a term referring to the use of a device to convert the effect of pelvic floor contraction into a visual or auditory response signal. It allows women and health professionals to observe improvement in an objective manner.

Electrical stimulation can assist in production of muscle contractions in women who either have extremely weak contractions or are unable to produce muscle contraction.

Vaginal cones have been developed as a way of applying graded resistance against which the pelvic floor muscle contract. Vaginal cones are thought to improve muscle activity to counteract gravity and downward movement.

In order to maximise the benefits that can be obtained using these techniques, it is vital to ensure that the treatment is supervised by a health professional.
Pharmacological management of SUI

Duloxetine is the only drug licensed for the treatment of SUI. It is a serotonin and noradrenaline reuptake inhibitor (SNRI) that enhances urethral striated sphincter activity via a centrally mediated pathway. Duloxetine is associated with significant and dose-dependent decreases in frequency of incontinence episodes. Nausea is the most frequently reported side-effect (up to 25%). Other side effects, including dyspepsia, dry mouth, insomnia or drowsiness, dizziness, can limit its use.

Surgery for SUI

Surgery for SUI can be considered when conservative measures have failed and the woman’s quality of life is compromised. It is important to be clear about the underlying cause of the incontinence, as the effects of surgery are largely irreversible. The options depend on the woman’s fitness for anaesthesia and whether there is any co-existing prolapse. Anterior colporrhaphy, the Marshall–Marchetti–Krantz procedure and needle suspensions are no longer recommended for the treatment of SUI.

Burch colposuspension used to be a "gold standard" procedure for many year with a success rate of 85–90%. The retropubic space is entered through a small suprapubic incision and two or three permanent sutures are placed on either side of the bladder neck to the corresponding ileopectineal ligament. This procedure can also be performed laparoscopically.

There is also a variety of "sling" procedures that can be performed abdominally or vaginally, with rectus sheath, fascia lata or synthetic materials. The commonest of these is the tension-free vaginal tape (TVT) procedure, which has a success rate of between 85 and 95%. TVT was first described by Ulmsten in 1995 and now is the most commonly performed surgical procedure for SUI in the UK. In the TVT procedure, a synthetic polypropylene tape is placed in a U-shape under the mid-urethra via a small vaginal incision, using local, regional or general anaesthesia. The tension is then adjusted to prevent leakage as the woman coughs. Cystourethroscopy is carried out to ensure that there has been no damage to the bladder or urethra. The procedure is minimally invasive and most women can return to normal activity within few weeks.

The Transobturator tape (TOT) procedure is similar to the TVT but a different technique is used to insert the tape. A polypropylene tape is passed via an obturator foramen, through the obturator and adductor muscles. The main difference from TVT is that with TOT the retropubic space is not entered. Consequently, the risk of bladder perforation is low. Early data suggest that this approach has a high success rate of 80–90%, similar to that of TVT.

Injectables or bulking agents are appropriate, if previous surgery has failed or in very elderly patients. Various compounds, including collagen, have been used with success rates of around 50%. Complications for all these procedures include post-operative voiding difficulty, bleeding, infection, de novo detrusor overactivity and suture or mesh erosion (in 'sling' procedures).

Conclusion

When managing urinary incontinence, doctors should also consider the patient’s medical history, co-existing health problems and any other pelvic floor dysfunction (eg. vaginal prolapse, faecal incontinence). It is important to treat predisposing factors, such as obesity, chronic cough, constipation and pelvic masses. Conservative treatment should always be offered before referral to hospital, and when conservative treatment is not effective or is declined by a woman, referral to a urogynaecologist in secondary care should be considered.

References

5. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and


